We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





MeMed Displays Disruptive Technology Award Finalist COVID-19 Severity Test at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: The MeMed Key platform (Photo courtesy of MeMed)
Image: The MeMed Key platform (Photo courtesy of MeMed)

MeMed (Haifa, Israel) displayed the MeMed COVID-19 Severity Test, the Disruptive Technology Award finalist, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the largest global scientific conference & tradeshow in the field of laboratory medicine.

MeMed was named a finalist for the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award for the MeMed COVID-19 Severity test, which stratifies the risk that a patient with COVID-19 will experience severe outcomes. It reads the immune-system in real time to accurately determine whether SARS-CoV-2 patients are likely to have a severe outcome.

MeMed COVID-19 Severity is a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 will experience severe outcomes. The test runs in 15 minutes on the company’s cutting edge multi-purpose platform, MeMed Key, for quantitative diagnostic immunoassays that opens the way to central lab performance at the point-of-need, using chemiluminescence detection technology. MeMed Key provides accuracy similar to large central lab immunoassay platforms in a miniaturized and point-of-need format. It has a wide dynamic range from single pg/ml to µg/ml, which opens the way to measuring host and pathogen based immunoassays that are currently only measurable at the central lab.

Also on display at the event was MeMed BV, a host-immune response assay that can aid to distinguish between bacterial and viral infections delivering results in 15 minutes from serum. MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response/co-infection versus a viral immune response. Run on the compact MeMed Key, it is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies.

Related Links:
MeMed 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.